Skip to main content
Top

Journal of Thrombosis and Thrombolysis

Issue 3/2002

Content (11 Articles)

Activated Clotting Times in the Setting of Eptifibatide Use During Percutaneous Coronary Intervention

Harold L. Dauerman, Steven A. Ball, Robert J. Goldberg, Melinda A. Desourdy, Mark I. Furman

The Smoker's Paradox: Insights from the Angiographic Substudies of the TIMI Trials

Brad G. Angeja, Sarah Kermgard, Michael S. Chen, Matthew McKay, Sabina A. Murphy, Elliott M. Antman, Christopher P. Cannon, Eugene Braunwald, C. Michael Gibson

Abciximab is Rapidly Effective in Preventing and Arresting Established Platelet Aggregation

Miles C. Dalby, Simon J. Davidson, John F. Burman, Ulrich Sigwart, Simon W. Davies

Feasibility and Timing of Prehospital Administration of Reteplase in Patients with Acute Myocardial Infarction

Donald G. Rosenberg, Esther Levin, Ana Lausell, Allen Brown, John Gardner, Esther Perez, Mark Veenendaal, Yee S.C. Ong, Mary Gunn

A Reconstituted In Vitro Clot Model for Evaluating Laser Thrombolysis

Abram D. Janis, Lisa A. Buckley, Abby N. Nyara, Scott A. Prahl, Kenton Gregory

The Association of Mondor's Disease with Protein S Deficiency: Case Report and Review of Literature

José Maria Pereira de Godoy, Moacir Fernandes Godoy, Fernando Batigália, Domingo Marcolino Braile

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine